Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven M. Paul M.D. | Founder & Independent Chairman | 568.99k | -- | 1951 |
| Mr. Abraham N. Ceesay M.B.A. | CEO, President, Treasurer & Director | 902.03k | -- | 1978 |
| Dr. Troy A. Ignelzi | Chief Financial Officer | 459.68k | -- | 1968 |
| Ms. Cheryl Gault | Chief Operating Officer | 281.11k | -- | 1979 |
| Mr. David Bredt M.D., Ph.D. | Founder & Chief Scientific Officer | -- | -- | 1965 |
| Ms. Karina Chmielewski | Chief Information Officer & Head of Operations | -- | -- | -- |
| Ms. Julie DiCarlo | Head of Communications & Investor Relations | -- | -- | -- |
| Ms. Kathleen A. Wilkinson | Chief People Officer | -- | -- | 1972 |
| Dr. Bradley S. Galer M.D. | Chief Medical Officer | -- | -- | 1962 |
| Mr. Swamy Yeleswaram Ph.D. | Chief Development Officer | -- | -- | 1963 |
Rapport Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 7, 2024 at 12:00 PM UTC
Rapport Therapeutics, Inc. Earnings Date